Funded PhD opportunity: HOX proteins as therapeutic targets in mesothelioma
This PhD involves the development of novel therapies and diagnostics in mesothelioma, a type of cancer that often occurs in the lungs and has a very poor prognosis. Our previous work showed that the HOX genes, a family of transcription factors with key roles in early development, are generally overexpressed in mesothelioma. The objectives of this study are to understand how mesothelioma can be treated using inhibitors of HOX function, and how HOX proteins and RNA transcripts can act as potential diagnostic markers for this disease.
This PhD will be based at the Institute for Cancer Therapeutics and is fully funded, including study fees (for home and EU students), bench fees, and a stipend to meet living costs. For more information please contact Prof Richard Morgan (email@example.com). The anticipated start date is September 2018.